Clinical trial Recruiting at 1 site Observational Ages 18 and up

Identifying risks of dangerous heart rhythms in genetic heart conditions

Official title: Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Run by Vanderbilt University Medical Center · NCT06575881 · Data updated 2026-11-12

This study is trying to see if special heart tests can help find people with genetic heart conditions who are at risk for serious heart rhythm problems.

More Atrial Fibrillation trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment200 (estimated)
SponsorVanderbilt University Medical Center
Academic / other
Locations1 site (Nashville, Tennessee)
StatusRecruiting
StartedDecember 13, 2023
Main results expectedDecember 2028
Study endsDecember 2029
Registry record updatedMay 6, 2026
Trial IDNCT06575881 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older diagnosed with atrial fibrillation, frequent premature ventricular contractions, or ventricular tachycardia before age 60, who are scheduled for catheter-based ablation procedures.

Probably not a fit

Patients with a prior diagnosis of a genetic cardiomyopathy or arrhythmia syndrome, or those with certain severe heart conditions, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to determine if electrophysiologic mapping and cardiac MRI can identify patients with genetic cardiomyopathies who are at high risk for developing dangerous ventricular arrhythmias. The study will assess the prevalence and mechanisms of inducible ventricular tachycardia, utilize pace-mapping to locate the origins of ventricular arrhythmias, and perform voltage mapping to identify low voltage scar substrates in the heart. Participants will undergo cardiac MRI and voltage mapping as part of the data collection process to enhance understanding of how genetic factors influence arrhythmia risk.

Why it matters

Potential benefit: If successful, this study could lead to improved risk stratification and management strategies for patients with genetic cardiomyopathies.

How similar studies have gone: Other studies have shown success in using genetic insights to inform clinical management of arrhythmias, making this approach both relevant and promising.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 18 and older
* Diagnosed with AF, frequent PVCs, or VT before age 60
* Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation
* Able to provide written, informed consent
* P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.

Exclusion Criteria:

* Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure
* VUS in 'possibly pathogenic' subgroup (control group only)
* Previous PVC or VT ablation
* LVEF \<20%
* Prosthetic mitral or aortic valve
* Contraindication to heparin
* Prior myocardial infarction

Where it's running

  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.